Case Studies

The MRCT Center has worked with stakeholders to develop case studies that illustrate (1) efforts for diversity, equity, and inclusion that have been successfully integrated into the clinical research enterprise, and (2) examples of therapeutic response differences that warrant investigation.

There are two types of case studies offered on this page: programmatic and therapeutic.

The programmatic case studies illustrate different organizational approaches to improve diversity in clinical trials, promote equity within their workplaces, build relationships with communities, and more.

The therapeutic case studies offer examples of differential treatment responses based on race, ethnicity, ancestry, and/or genetic variability.

The case highlights offer a case overview focusing on key takeaways while the full case studies provide further detail, explanation, and examples.

Programmatic Case Studies

Case Study

Description

Links

Achieving and Exceeding Clinical Trial Participant Diversity Targets

How Merck increased clinical trial diversity using Customized Tools, Applications, and a Dynamic Enrollment Tracker

All of Us Research Program

How a large, unprecedented national study ensured over 80% enrollment of historically underrepresented participants

Data-driven Diversity Assessments at a Medical Device Company

How Boston Scientific utilizes data to systematically prioritize racial and ethnic diversity in cardiovascular treatment and clinical trials

Diverse Patient Engagement at a Pharmaceutical Company

Sanofi Genzyme’s approach to involve patients in clinical trial development

Diverse Recruitment at Yale Center for Clinical Investigation

Yale School of Medicine’s integrative approach to recruit a diverse patient population for research

Embedding Diversity & Inclusion within a Pharmaceutical Company

How Biogen included Diversity & Inclusion within and across the organization’s culture and strategy

Multiple Sclerosis Research Mythbusting Series

How Accelerated Cure Project (ACP) and the Multiple Sclerosis Association of America (MSAA) collaborated to further diverse clinical trial participation

Therapeutic Case Studies

Case Study

Description

Links

Bucindolol

How genetic differences may contribute to different efficacies in treatment response

Clopidogrel

How differences in treatment response between different racial or ethnic subgroups can lead to important observations in drug discovery and development

Omapatrilat

How diverse participation in clinical trials can reveal differing safety profiles of a treatment

PCSK9

How racial and ethnic diversity identified important genetic variants that aided drug discovery and development